Aspira Women's Health Inc.Find Ratings Reports
ASPIRA WOMENS HEALTH INC's gross profit margin for the third quarter of its fiscal year 2020 has significantly increased when compared to the same period a year ago. Sales and net income have dropped, although the growth in revenues underperformed the average competitor within the subsector, the net income growth did not. ASPIRA WOMENS HEALTH INC is extremely liquid. Currently, the Quick Ratio is 4.27 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 23.02% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY20||Q3 FY19|
|Net Sales ($mil)||1.24||1.29|
|Net Income ($mil)||-4.29||-3.82|
|Balance Sheet||Q3 FY20||Q3 FY19|
|Cash & Equiv. ($mil)||18.84||14.64|
|Total Assets ($mil)||21.27||16.53|
|Total Debt ($mil)||2.59||1.42|
|Profitability||Q3 FY20||Q3 FY19|
|Gross Profit Margin||40.03||30.89|
|Return on Assets||-71.53||-88.73|
|Return on Equity||-104.54||-124.04|
|Debt||Q3 FY20||Q3 FY19|
|Share Data||Q3 FY20||Q3 FY19|
|Shares outstanding (mil)||104.04||97.24|
|Div / share||0.0||0.0|
|Book value / share||0.14||0.12|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||596664.0||738905.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 42.19 indicates a significant premium versus the S&P 500 average of 4.08 and a significant premium versus the subsector average of 10.52. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. Upon assessment of these and other key valuation criteria, ASPIRA WOMENS HEALTH INC seems to be trading at a premium to investment alternatives.
|AWH NM||Peers 82.33||AWH NM||Peers 93.90|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AWH's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AWH's P/CF is negative making the measure meaningless.
|AWH NM||Peers 68.99||AWH NA||Peers 3.71|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
AWH's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AWH 42.19||Peers 10.52||AWH 21.06||Peers 20.51|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AWH is trading at a significant premium to its peers.
Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
AWH is expected to keep pace with its peers on the basis of earnings growth.
|AWH 136.11||Peers 12.11||AWH 8.69||Peers 18.40|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AWH is trading at a significant premium to its subsector.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
AWH significantly trails its peers on the basis of sales growth.